ApoGen Biotechnologies

OverviewSuggest Edit

ApoGen Biotechnologies is developing novel oncology therapeutics targeting the key drivers of mutation and cancer genomic evolution to overcome drug resistance. Our lead target is APOBEC3B (A3B), a DNA cytosine deaminase and an important endogenous source of DNA mutation in cancer. A3B was recently identified as a dominant source of the characteristic C-to-T mutational pattern and higher overall mutational load seen in numerous cancers. Elevated levels of A3B were shown to be a key driver in the formation of cancers including breast, head and neck, lung, bladder, cervical, ovarian, myeloma, and some blood cancers. ApoGen’s drug discovery and development efforts are directed toward highly selective and potent small molecule inhibitors of A3B. These inhibitors aim to slow or stop cancer genome mutation and the development of drug resistance, potentially increasing the effectiveness of current and future therapies.
TypePrivate
Founded2014
HQSeattle, US
Websiteapogenbiotech.com

Locations

ApoGen Biotechnologies is headquartered in
Seattle, United States

Location Map

Latest Updates

Employees (est.) (May 2020)10

Key People/Management at ApoGen Biotechnologies

Peter de Vries

Peter de Vries

PhD Senior Director, Biology
Stephen Gwaltney

Stephen Gwaltney

PhD Vice President, Chemistry
John Santini

John Santini

PhD, Founder
Reuben Harris

Reuben Harris

PhD, Founder
Daniel Harki

Daniel Harki

PhD Founder
Show more

ApoGen Biotechnologies Office Locations

ApoGen Biotechnologies has an office in Seattle
Seattle, US (HQ)
2815 Eastlake Ave E #300
Show all (1)

ApoGen Biotechnologies Financials and Metrics

Summary Metrics

Founding Date

2014

ApoGen Biotechnologies total Funding

$11 m

ApoGen Biotechnologies latest funding size

$4 m

Time since last funding

2 years ago

ApoGen Biotechnologies investors

ApoGen Biotechnologies's latest funding round in August 2018 was reported to be $4 m. In total, ApoGen Biotechnologies has raised $11 m
Show all financial metrics

ApoGen Biotechnologies Online and Social Media Presence

Embed Graph

ApoGen Biotechnologies Frequently Asked Questions

  • When was ApoGen Biotechnologies founded?

    ApoGen Biotechnologies was founded in 2014.

  • Who are ApoGen Biotechnologies key executives?

    ApoGen Biotechnologies's key executives are Peter de Vries, Stephen Gwaltney and John Santini.

  • How many employees does ApoGen Biotechnologies have?

    ApoGen Biotechnologies has 10 employees.

  • Who are ApoGen Biotechnologies competitors?

    Competitors of ApoGen Biotechnologies include Wuhan Healthgen Biotechnology, Virun and Roivant Sciences.

  • Where is ApoGen Biotechnologies headquarters?

    ApoGen Biotechnologies headquarters is located at 2815 Eastlake Ave E #300, Seattle.

  • Where are ApoGen Biotechnologies offices?

    ApoGen Biotechnologies has an office in Seattle.

  • How many offices does ApoGen Biotechnologies have?

    ApoGen Biotechnologies has 1 office.